Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

663
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
663
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

699
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
699
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

232
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
232
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autonomic Dysfunction in Long COVID Is Distinct From Pure Autonomic Failure.

Journal of the American College of Cardiology·2026
Same author

Test-retest reliability of clinical supine-to-stand tests in patients with postural orthostatic tachycardia syndrome: A cautionary tale.

Heart rhythm·2026
Same author

Why the Second-Hit Hypothesis Merits Center Stage in Peripherally Induced Movement Disorders?

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia.

Annals of clinical and translational neurology·2025
Same author

A wolf in synuclein clothing: Creutzfeldt-Jakob disease disguised as MSA.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2025
Same author

Clinical Reasoning: A 66-Year-Old Man With Chronic Orthostatic Hypotension.

Neurology·2025

Related Experiment Video

Updated: May 23, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.2K

Carbidopa: beyond Parkinson's disease.

Abhishek Lenka1, Steven Vernino2

  • 1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA. abhishek.lenka@utsouthwestern.edu.

Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society
|March 8, 2025
PubMed
Summary

Carbidopa, beyond Parkinson's disease, shows promise for autonomic disorders like familial dysautonomia and POTS. It effectively manages nausea and sympathetic hyperactivity with a favorable safety profile.

Keywords:
Autonomic dysfunctionBaroreflex dysfunctionCarbidopaDysautonomiaPOTS

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Related Experiment Videos

Last Updated: May 23, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.2K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.9K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Area of Science:

  • Pharmacology
  • Neurology
  • Internal Medicine

Background:

  • Carbidopa is primarily known for its role in Parkinson's disease management.
  • Autonomic disorders present complex challenges in patient care.
  • Understanding novel therapeutic applications is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the pharmacology and real-world applications of carbidopa.
  • To explore carbidopa's utility in managing autonomic disorders beyond Parkinson's disease.

Main Methods:

  • A comprehensive literature search was performed on PubMed.
  • Keywords used included "Carbidopa," "MK-486," and "L-alpha-methyldopa hydrazine."
  • Articles were selected for review in January 2025.

Main Results:

  • Carbidopa demonstrated efficacy in treating nausea and sympathetic hyperactivity in familial dysautonomia, hyperadrenergic POTS, and afferent baroreflex failure.
  • High doses (up to 600 mg/day) were generally well-tolerated in clinical trials for familial dysautonomia.
  • Pre-clinical data suggest carbidopa may inhibit T-cell activation and have potential in cytokine release syndrome.

Conclusions:

  • Carbidopa exhibits a favorable safety profile for autonomic disorder management.
  • Limited evidence suggests carbidopa's utility in treating nausea and sympathetic hyperactivity symptoms.
  • Further large-scale studies are needed to confirm carbidopa's therapeutic role in these conditions.